Market closed
Century Therapeutics/$IPSC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Century Therapeutics
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Ticker
$IPSC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
159
Website
IPSC Metrics
BasicAdvanced
$70M
-
-$1.80
1.42
-
Price and volume
Market cap
$70M
Beta
1.42
52-week high
$5.51
52-week low
$0.82
Average daily volume
584K
Financial strength
Current ratio
10.394
Quick ratio
10.064
Long term debt to equity
25.979
Total debt to equity
25.979
Management effectiveness
Return on assets (TTM)
-20.90%
Return on equity (TTM)
-62.61%
Valuation
Price to revenue (TTM)
22.201
Price to book
0.36
Price to tangible book (TTM)
0.44
Price to free cash flow (TTM)
-0.527
Growth
Revenue change (TTM)
7.88%
Earnings per share change (TTM)
-17.95%
3-year earnings per share growth (CAGR)
-23.78%
What the Analysts think about IPSC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Century Therapeutics stock.
IPSC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
IPSC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
IPSC News
AllArticlesVideos
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewsWire·2 months ago
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
GlobeNewsWire·3 months ago
Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Century Therapeutics stock?
Century Therapeutics (IPSC) has a market cap of $70M as of January 31, 2025.
What is the P/E ratio for Century Therapeutics stock?
The price to earnings (P/E) ratio for Century Therapeutics (IPSC) stock is 0 as of January 31, 2025.
Does Century Therapeutics stock pay dividends?
No, Century Therapeutics (IPSC) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Century Therapeutics dividend payment date?
Century Therapeutics (IPSC) stock does not pay dividends to its shareholders.
What is the beta indicator for Century Therapeutics?
Century Therapeutics (IPSC) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.